Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Emulate
January 27, 2014
Medigene’s long hunting trip pulls down an immunotherapy company
January 13, 2014
Alnylam lives the biotech dream as big pharma returns to RNAi
November 01, 2013
EP Vantage interview – Arrowhead looks to evolve beyond the chimp
October 15, 2013
Astra moves to emulate Kadcyla, courtesy of Spirogen
September 20, 2013
Prosensa's phase III flop could have broad implications for exon-skipping
March 15, 2012
Interview - Affimed hoping to crank up the pace
May 05, 2010
Renal saftety signal slows GSK trial of sirtuins
April 22, 2010
EP Vantage Interview - Heptares seeking partner to back clinical work
November 06, 2009
Genmab cuts costs and jobs as it goes back to its roots
June 19, 2009
NicOx's hint of deal delay makes fundraising look likely
November 24, 2008
Event – NicOx limbering up for final data hurdle
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
November 16, 2021
Covid Round Up (2021)
November 16, 2021
Covid Round Up (2021)
Editor's Picks
November 22, 2021
The bubble bursts for biotech stocks
November 08, 2021
Ash 2021 preview – as competition grows Autolus monetises
November 23, 2021
Ash 2021 late-breakers enable neat comparisons
November 04, 2021
What Novartis could buy with its windfall
November 16, 2021
Fate buries bad data and moves on
